Navigation Links
Genus Oncology, LLC Announces Orphan Drug Status for GO-203-2c for Treatment of Pancreatic Cancer
Date:3/8/2011

VERNON HILLS, Ill., March 8, 2011 /PRNewswire/ -- Genus Oncology, LLC, a clinical-stage company focused on commercializing novel drugs for treatment of cancer, announced it has received an Orphan Drug Designation from the FDA's Office of Orphan Products Development for its Mucin 1 (MUC1) targeting peptide, GO-203-2c, for the treatment of pancreatic cancer.

Orphan Drug Designation, as granted by the US Orphan Drug Act, is for a product that treats a rare disease or condition affecting fewer than 200,000 people in the US. According to the National Cancer Institute, there are approximately 31,000 people diagnosed with pancreatic cancer in the US annually, and approximately 220,000 worldwide. Orphan Drug Designation qualifies the sponsor of the product for tax credits and seven years of marketing exclusivity, among other benefits.  

"Treatment of pancreatic cancer represents a significant unmet medical need," said Stephen Thompson, CEO and President of Genus Oncology. "Pancreatic cancer is the fourth most common cause of cancer-related deaths in the Western world, and survival rates of patients diagnosed with pancreatic cancer have not changed in decades despite advances in treatment options. Based on our results of treating pancreatic cancer in preclinical models, we believe our MUC1 targeting technologies have the potential to significantly impact the treatment and outcomes of this difficult to treat disease."

GO-203-2c, Genus' lead drug candidate, is currently being studied in a Phase I trial that is designed to determine the safety and tolerability, and potential anti-tumor activity of the drug. The sites currently contracted to conduct the Phase I trial are the University of Texas Health Science Center at San Antonio (UTHSCSA) and the Virginia G. Piper Cancer Center at Scottsdale Healthcare. Additional sites are currently under consideration.

About GO-203-2c

GO-203-2c is the optimized lead peptide drug candidate from a series of first-in-class agents synthesized to target MUC1, an oncoprotein that is overexpressed in many diverse human carcinomas including breast, prostate, lung, colon, pancreatic, and ovarian that have been associated with poor prognosis. Of an estimated 1.4 million cancer cases diagnosed each year in the US, about 900,000 overexpress MUC1, thus making it an attractive target for developing anti-cancer drugs. To date, there are no approved agents that target MUC1.

About Genus Oncology, LLC

Genus Oncology, LLC, is a clinical-stage company formed in 2007 with a mission of discovering, developing, and commercializing new anti-cancer agents that target the MUC1 oncoprotein. Genus' intellectual capital includes more than 20 years of research at Dana-Farber Cancer Institute (DFCI) and Harvard Medical School, and a senior management team with significant pharmaceutical industry experience leading successful discovery, development, and commercialization initiatives. For more information, please visit www.genusoncology.com.


'/>"/>
SOURCE Genus Oncology, LLC
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Genus Oncology, LLC Announces Initiation of Phase I Trial of GO-203-2c in Patients With Solid Tumors
2. US Oncology, Inc. to Exhibit iKnowMed(TM) at the 2009 ASCO EHR Symposium: Harnessing the EHR: From Incentives to Sustainability
3. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
4. EDAP Announces Launch of Clinical Study Combining HIFU and Chemotherapy for Localized Aggressive High Risk Prostate Cancer
5. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
6. ADVENTRX Announces Fast Track Designation Granted By the FDA For CoFactor For the Treatment of Metastatic Colorectal Cancer
7. DOV Pharmaceutical, Inc. Announces Successful Phase Ib Results for DOV 21,947
8. Phosphagenics Announces Positive Phase 1b Transdermal Insulin Clinical Trial Results
9. Xenomics Announces Implementation of its First Diagnostic Test for Acute Myeloid Leukemia Into Clinical Practice
10. Emisphere Technologies, Inc. Announces 2007 Second Quarter Financial Results
11. Amicus Therapeutics Announces Second Quarter 2007 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/4/2016)... , Feb. 4, 2016   Bernstein Liebhard LLP ... filed in the United States District Court for the District ... class (the "Class") consisting of all persons or entities who ... "Company") (NASDAQ: INSY ) from March 3, 2015 through ... and certain of its officers with violations of the Securities ...
(Date:2/4/2016)... Feb. 4, 2016 Summary Breast cancer, ... and the most common cancer in women worldwide, accounting ... exceedingly prevalent. The number of women diagnosed with breast ... the number of deaths has declined due to earlier ... has been revolutionized in the past four decades, especially ...
(Date:2/4/2016)... Feb. 4, 2016 Mettler-Toledo International Inc. (NYSE: ... 2015.  Provided below are the highlights: , ... compared with the prior year.  Reported sales decreased 3% ... quarter. , Net earnings per diluted share as ... prior- year period.  Adjusted EPS was $4.65, an increase ...
Breaking Medicine Technology:
(Date:2/6/2016)... ... February 06, 2016 , ... ... EXPECTED AT AORN SURGICAL CONFERENCE & EXPO , WHAT:     , This conference ... estimated 5000 perioperative nurses in attendance to study the latest evidence-based recommendations ...
(Date:2/6/2016)... ... ... Shark Finds and Kevin Harrington, along with the Product Managers ... Belly Bands. , Having a dog is great—except when it wets every couch, bed, ... works, get Belly Bands, the easiest way to stop dogs from wetting on ...
(Date:2/5/2016)... NY (PRWEB) , ... February 05, 2016 , ... Love ... long-stem roses in a variety of colors, assortments and packaging. This staple for Valentine’s ... any King Kullen location. , For Valentine’s Day, not only are long-stem roses ...
(Date:2/5/2016)... ... February 05, 2016 , ... Successful recruitment ... new clinical and scientific initiatives have all marked the last 12 months at ... and CEO of the nation’s oldest cancer center, Candace S. Johnson, PhD, outlined ...
(Date:2/5/2016)... ... February 05, 2016 , ... Francisco Canales, MD and ... their Napa Valley office. The technique utilizes the body’s own healing abilities to ... Dr. Furnas, are part of only a select few cosmetic surgeons bringing this ...
Breaking Medicine News(10 mins):